You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
首批77萬劑復必泰二價疫苗抵港 下月1日開打
阿思達克 11-26 09:49
復星醫藥昨日(25日)將首批約77萬劑復必泰二價疫苗運送抵港。公務員事務局局長楊何蓓茵在電台節目表示,下月1日(下周四)將正式開打復必泰二價疫苗,市民明日(27日)起預約第四劑新冠疫苗時可以選擇接種。 政府指,按專家建議,復必泰二價疫苗可供12歲或以上合資格人士按現時的接種時間表,用作第四劑疫苗或康復人士接種第三劑疫苗的另一選擇,但他們仍可選擇接種科興或復必泰原始病毒株疫苗。 專家建議兩類人士應接種第四劑疫苗(或康復人士作為接種第三劑疫苗),包括50歲或以上人士;12歲或以上免疫力弱人士。此外,18至49歲人士經考慮對自身的風險和益處,例如有較高暴露風險或個人需要,亦可接種第四劑疫苗。 政府提到,已向藥廠採購共190萬劑復必泰二價疫苗,餘下的劑量預計將於年底前運送抵港,並會密切留意二價疫苗的需求,在有需要時增購。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account